Navigation Links
New antidepressant acts very rapidly and is long lasting
Date:12/7/2012

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.

The novel therapeutic targets brain receptors responsible for learning and memory -- a very different approach from existing antidepressants. The new drug and others like it also could be helpful in treating other neurological conditions, including schizophrenia, bipolar disorder, anxiety and Alzheimer's disease.

The results of the phase IIa clinical trial were presented today (Dec. 6) at the 51st Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, Fla.

Also this week, a paper reporting some of the background scientific research that provided the foundation for the clinical development of GLYX-13 was published by the journal Neuropsychopharmacology.

The compound, called GLYX-13, is the result of more than two decades of work by Joseph Moskal, research professor of biomedical engineering at Northwestern's McCormick School of Engineering and Applied Science and director of the University's Falk Center for Molecular Therapeutics.

"Our study showed that this compound is capable of eliciting a robust and rapid antidepressant effect without the typical side effects seen with other drugs that also modulate the NMDA receptor," said Moskal, who is founder and chief scientific officer of the Evanston-based biotechnology company Naurex Inc., which conducted the clinical study.

GLYX-13 works by modulating the NMDA (N-methyl-D-aspartate) receptor in the brain, as do current NMDA receptor antagonists such as ketamine, but GLYX-13 does not have their serious and limiting side effects, such as hallucinations and schizophrenia-like effects. (An antagonist is a substance that inhibit
'/>"/>

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Brain signal IDs responders to fast-acting antidepressant
2. Research finds heart remodeling rapidly follows cardiac injury
3. New study reveals lions are rapidly losing ground in Africa
4. Bears, scavengers count on all-you-can-eat salmon buffet lasting for months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... in German . ... drugs. When treating overdoses, doctors are often limited to supportive ... there is a combination of drugs involved. So what can ... his grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute ... answer to this question. "The task was to develop an ...
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
(Date:10/15/2014)... our ability to assess the pandemic risk from strains ... we must not allow ourselves to become complacent that ... international consortium of scientists. , Influenza pandemics arise when ... yet to develop widespread immunity – spreads in the ... the past 100 years, the worst of which – ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... The 2010 Annual Meeting & OTO EXPO of the American ... the largest meeting of ear, nose, and throat doctors in ... official abstract supplement for the annual meeting is now available ... Otolaryngology Head and Neck Surgery . (See new ...
... a genetic route to understanding and treating epilepsy. Timothy ... has identified an ancient gene family that plays a role ... "In healthy people, nerves do not fire excessively in response ... on what really matters. Nerve cells maintain a threshold ...
... Eliza Hall Institute researchers in Melbourne, Australia, have made ... cell death and its role in tumour formation. ... process in human biology as it removes unwanted and ... against cancer development and autoimmune disease. The ...
Cached Biology News:Otolaryngology -- Head and Neck Surgery Annual Meeting supplement now available 2Epileptic seizures may be linked to an ancient gene family 2Missing Puma reveals cancer conundrum 2Missing Puma reveals cancer conundrum 3
(Date:10/18/2014)... (PRWEB) October 19, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers, restraints, challenges, opportunities, current market trends, ... along with the estimates and forecasts of the ...
(Date:10/18/2014)... The Asian arthroscopic devices report defines and segments the ... revenue. The arthroscopic devices market in Asia is estimated ... CAGR of 6.5% from 2013 to 2018. , Browse ... to get an idea of the in-depth analysis provided. ... arthroscopic devices market in the same region, and is ...
(Date:10/18/2014)... The Asian Electronic Medical Record (EMR) market ... analysis and forecast of revenue. The electronic medical record market ... million by 2018, at a CAGR of 9.4% from 2013 ... Electronic Medical Record (EMR) market, to get an idea of ... the segmentation of the market in the same region, and ...
(Date:10/18/2014)... The report " Cloud Analytics ... Web; Speech; Machine; Video; Predictive Analytics: Global Advancements, ... & Analysis (2013 - 2018) ", defines and ... sub segments with an in-depth analysis and forecasting ... factors driving this market, various restraints, and opportunities ...
Breaking Biology Technology:Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5
... in ... ... CHDX ) a leading independent American provider of Western,healthcare services ... has agreed to an investment by JPMorgan,s Principal,Investment Management group. The ...
... Nov. 7 Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast: ... Conference Call, ... Where: http://www.transgenomic.com/events.asp?id=6 , How: ... at the ...
... - Nventa,Biopharmaceuticals Corporation (TSX: NVN) announced today financial results,for ... unless,specified otherwise, are in Canadian dollars. Nventa reported ... share, for the,three months ended September 30, 2007, compared ... share, for the same period in 2006. For the ...
Cached Biology Technology:JPMorgan's Principal Investment Management Group to Invest in Chindex International, Inc. 2JPMorgan's Principal Investment Management Group to Invest in Chindex International, Inc. 3Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast 2Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 2Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 3Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 4
... (ELISA) test kits are qualitative one-step kits ... of drugs and/or their metabolites in forensic ... use only. It is recommended that all ... method such as GC/MS. The simple ...
96 Well Base Plate...
... a recombinant human protein produced in E. coli ... RNase A type enzymes. The mode of ... in a 1:1 ratio. The enzyme has been ... and cell types. Addition of the ribonuclease inhibitor ...
... Inkjet Printer) is a revolutionary new ... Protein Macroarray Analysis, developed in conjunction ... strategy compliments established protocols in resolving ... proteins isoelectric point and apparent molecular ...
Biology Products: